Concepedia

Aaron Tieman

AT

Statistics

Publications

3

Citations

343

H-Index

3

Active since

1999

Affiliations

Bristol-Myers Squibb (United States)(Current)

Aaron Tieman is an author at Bristol-Myers Squibb (United States) specializing in molecular pharmacology, pharmacology, and antidiabetic drug therapy.

Publications per year

1999–2006

3

Publications

3

Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: A sequestration mechanism in metabolic regulation

Dennis Farrelly, Karen Brown, Aaron Tieman et al. · Proceedings of the National Academy of Sciences · 1999 · 155 citations

, , +16

Design and Synthesis of <i>N</i>-[(4-Methoxyphenoxy)carbonyl]-<i>N</i>-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities

Pratik Devasthale, Sean Chen, Yoon Jeon et al. · Journal of Medicinal Chemistry · 2004 · 108 citations · Full text

, , +13

Muraglitazar, a Novel Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves β-Cell Function in <i>db/db</i> Mice

Thomas Harrity, Dennis Farrelly, Aaron Tieman et al. · Diabetes · 2006 · 80 citations · Full text

, , +16

1–3 of 3